DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$5.75B
(+6.1%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
64
Reduced
46
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Integra LifeSciences
IART
$1.18B
| $52.2M | 0.91% |
1,473,090
+344,091
| +30% | +$12.2M |
|
27
Galapagos
GLPG
$2.06B
| $45.4M | 0.79% |
1,411,000
+788,888
| +127% | +$25.4M |
|
28
Structure Therapeutics
GPCR
$1.14B
| $44.3M | 0.77% |
1,033,680
+210,867
| +26% | +$9.04M |
|
29
Disc Medicine
IRON
$2.14B
| $41.4M | 0.72% |
665,535
+201,243
| +43% | +$12.5M |
|
30
Alignment Healthcare
ALHC
$3.23B
| $41M | 0.71% |
8,270,697
+4,781,889
| +137% | +$23.7M |
|
|
31
Viking Therapeutics
VKTX
$3.02B
| $38M | 0.66% |
463,501
-815,499
| -64% | -$66.9M |
|
|
32
Kyverna Therapeutics
KYTX
$161M
| $36.3M | 0.63% |
+1,462,337
| New | +$36.3M |
|
33
Embecta
EMBC
$837M
| $36.2M | 0.63% |
2,726,135
+1,341,296
| +97% | +$17.8M |
|
|
34
Perspective Therapeutics
CATX
$251M
| $33.5M | 0.58% |
+28,177,636
| New | +$33.5M |
|
35
Solid Biosciences
SLDB
$448M
| $30.1M | 0.52% |
+2,260,398
| New | +$30.1M |
|
36
Day One Biopharmaceuticals
DAWN
$766M
| $29.2M | 0.51% |
1,765,312
+4,134
| +0.2% | +$68.3K |
|
37
CONMED
CNMD
$1.64B
| $27.1M | 0.47% |
338,165
+335,609
| +13,130% | +$26.9M |
|
38
BioCryst Pharmaceuticals
BCRX
$1.74B
| $25.4M | 0.44% |
4,995,000
+455,475
| +10% | +$2.31M |
|
39
InMode
INMD
$917M
| $25.2M | 0.44% |
+1,166,704
| New | +$25.2M |
|
|
ACCD
40
DELISTED
Accolade, Inc. Common Stock
ACCD
| $25M | 0.43% |
+2,382,102
| New | +$25M |
|
41
Pharvaris
PHVS
$1.41B
| $24.5M | 0.43% |
1,061,592
+249,356
| +31% | +$5.76M |
|
|
AUTL
42
Autolus Therapeutics
AUTL
$383M
| $23.2M | 0.4% |
+3,639,000
| New | +$23.2M |
|
43
Apogee Therapeutics
APGE
$2.27B
| $21.9M | 0.38% |
+329,000
| New | +$21.9M |
|
44
Cabaletta Bio
CABA
$144M
| $21.5M | 0.37% |
1,258,650
-749,079
| -37% | -$12.8M |
|
45
DocGo
DCGO
$152M
| $20.6M | 0.36% |
5,104,387
-215,752
| -4% | -$872K |
|
46
Castle Biosciences
CSTL
$673M
| $20.6M | 0.36% |
928,017
-37,411
| -4% | -$829K |
|
47
Prelude Therapeutics
PRLD
$69.1M
| $19.6M | 0.34% |
4,133,000
| – | – |
|
48
Ventyx Biosciences
VTYX
$184M
| $19.5M | 0.34% |
+3,542,000
| New | +$19.5M |
|
49
Cullinan Oncology
CGEM
$456M
| $19.4M | 0.34% |
+1,138,531
| New | +$19.4M |
|
50
Insulet
PODD
$24.2B
| $18.9M | 0.33% |
110,061
-68,859
| -38% | -$11.8M |
|